Soligenix Inc. announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the BIO Investment & Growth Summit on March 2 at 3 p.m. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Florida, will feature presentations, one-on-one meetings, and programming focused on growth-stage biotechnology companies. Additional information is available on the conference website.
The presentation is significant as it provides visibility for Soligenix's late-stage pipeline targeting rare diseases with substantial unmet medical needs. The company's Specialized BioTherapeutics segment is advancing HyBryte (SGX301) toward potential commercialization as a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Following successful completion of a second Phase 3 study, the company plans to seek regulatory approvals worldwide. This development matters because CTCL is a rare cancer with limited treatment options, and HyBryte represents a new therapeutic approach using safe visible light.
Beyond CTCL, Soligenix is expanding synthetic hypericin (SGX302) into psoriasis and developing first-in-class innate defense regulator technology, including dusquetide (SGX942) for inflammatory diseases like oral mucositis in head and neck cancer patients, and SGX945 for Behcet's Disease. These programs address conditions where patients often face significant morbidity and limited effective therapies.
The company's Public Health Solutions segment includes vaccine candidates for ricin toxin, filoviruses like Marburg and Ebola, and CiVax for COVID-19 prevention. These programs incorporate Soligenix's proprietary ThermoVax heat stabilization platform technology, which could enable vaccine distribution without stringent cold chain requirements. This segment has been supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority.
The BIO Investment & Growth Summit presentation represents an opportunity for Soligenix to communicate its progress to investors and industry stakeholders. For patients with rare diseases, the company's pipeline represents potential new treatment options where few exist. The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX. The broader implications extend to healthcare systems seeking effective treatments for rare conditions and public health preparedness against biological threats.
